ID   ENOX2_HUMAN             Reviewed;         610 AA.
AC   Q16206; A8K197; A8K1C2; Q5VTJ1; Q5VTJ2; Q8WUX0; Q9NTP6; Q9UH82;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   19-SEP-2003, sequence version 2.
DT   28-JUN-2023, entry version 183.
DE   RecName: Full=Ecto-NOX disulfide-thiol exchanger 2;
DE   AltName: Full=APK1 antigen;
DE   AltName: Full=Cytosolic ovarian carcinoma antigen 1;
DE   AltName: Full=Tumor-associated hydroquinone oxidase;
DE            Short=tNOX;
DE   Includes:
DE     RecName: Full=Hydroquinone [NADH] oxidase;
DE              EC=1.-.-.-;
DE   Includes:
DE     RecName: Full=Protein disulfide-thiol oxidoreductase;
DE              EC=1.-.-.-;
GN   Name=ENOX2; Synonyms=COVA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVITY REGULATION, MUTAGENESIS OF
RP   MET-396; CYS-505; CYS-510; HIS-546; CYS-558; HIS-562; CYS-569; CYS-575;
RP   GLY-592 AND CYS-602, AND COFACTOR.
RX   PubMed=11888291; DOI=10.1021/bi012041t;
RA   Chueh P.-J., Kim C., Cho N., Morre D.M., Morre D.J.;
RT   "Molecular cloning and characterization of a tumor-associated, growth-
RT   related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa
RT   cell surface.";
RL   Biochemistry 41:3732-3741(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORMS 1 AND 2).
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 17-405.
RA   Rhodes S., Huckle E.;
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PROTEIN SEQUENCE OF 86-90; 249-266 AND 318-333.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=11437345; DOI=10.1006/abbi.2001.2404;
RA   Yantiri F., Morre D.J.;
RT   "Isolation and characterization of a tumor-associated NADH oxidase (tNOX)
RT   from the HeLa cell surface.";
RL   Arch. Biochem. Biophys. 391:149-159(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 275-610, SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION.
RC   TISSUE=Ovarian carcinoma;
RX   PubMed=8150545; DOI=10.1002/ijc.2910570117;
RA   Chang K., Pastan I.;
RT   "Molecular cloning and expression of a cDNA encoding a protein detected by
RT   the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line.";
RL   Int. J. Cancer 57:90-97(1994).
RN   [9]
RP   ACTIVITY REGULATION.
RX   PubMed=9046026; DOI=10.1023/a:1006866726050;
RA   Dai S., Morre D.J., Geilen C.C., Almond-Roesler B., Orfanos C.E.,
RA   Morre D.M.;
RT   "Inhibition of plasma membrane NADH oxidase activity and growth of HeLa
RT   cells by natural and synthetic retinoids.";
RL   Mol. Cell. Biochem. 166:101-109(1997).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ACTIVITY REGULATION.
RX   PubMed=9932650; DOI=10.1023/a:1020594214379;
RA   Morre D.J., Chueh P.-J., Lawler J., Morre D.M.;
RT   "The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma
RT   membranes has properties of a protein disulfide-thiol oxidoreductase with
RT   protein disulfide-thiol interchange activity.";
RL   J. Bioenerg. Biomembr. 30:477-487(1998).
RN   [11]
RP   HYDROQUINONE OXIDASE ACTIVITY.
RX   PubMed=10354495; DOI=10.1016/s0005-2728(99)00049-3;
RA   Kishi T., Morre D.M., Morre D.J.;
RT   "The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase
RT   activity.";
RL   Biochim. Biophys. Acta 1412:66-77(1999).
RN   [12]
RP   PRION-LIKE PROPERTIES.
RX   PubMed=11412089; DOI=10.1021/bi010596i;
RA   Kelker M., Kim C., Chueh P.-J., Guimont R., Morre D.M., Morre D.J.;
RT   "Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) has
RT   properties of a prion.";
RL   Biochemistry 40:7351-7354(2001).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11488599; DOI=10.1006/abbi.2001.2436;
RA   Morre D.J., Sedlak D., Tang X., Chueh P.-J., Geng T., Morre D.M.;
RT   "Surface NADH oxidase of HeLa cells lacks intrinsic membrane binding
RT   motifs.";
RL   Arch. Biochem. Biophys. 392:251-256(2001).
RN   [14]
RP   DISEASE.
RX   PubMed=11941450; DOI=10.1007/s00262-001-0262-2;
RA   Cho N., Chueh P.-J., Kim C., Caldwell S., Morre D.M., Morre D.J.;
RT   "Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone
RT   (NADH) oxidase from the sera of cancer patients.";
RL   Cancer Immunol. Immunother. 51:121-129(2002).
RN   [15]
RP   FUNCTION IN BIOLOGICAL CLOCK CONTROL.
RX   PubMed=12356293; DOI=10.1021/bi020392h;
RA   Morre D.J., Chueh P.-J., Pletcher J., Tang X., Wu L.Y., Morre D.M.;
RT   "Biochemical basis for the biological clock.";
RL   Biochemistry 41:11941-11945(2002).
RN   [16]
RP   VARIANT ILE-202.
RX   PubMed=23033978; DOI=10.1056/nejmoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C.,
RA   del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G.,
RA   Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: May be involved in cell growth. Probably acts as a terminal
CC       oxidase of plasma electron transport from cytosolic NAD(P)H via
CC       hydroquinones to acceptors at the cell surface. Hydroquinone oxidase
CC       activity alternates with a protein disulfide-thiol
CC       interchange/oxidoreductase activity which may control physical membrane
CC       displacements associated with vesicle budding or cell enlargement. The
CC       activities oscillate with a period length of 22 minutes and play a role
CC       in control of the ultradian cellular biological clock.
CC       {ECO:0000269|PubMed:12356293, ECO:0000269|PubMed:9932650}.
CC   -!- COFACTOR:
CC       Name=Cu cation; Xref=ChEBI:CHEBI:23378;
CC         Evidence={ECO:0000269|PubMed:11888291};
CC   -!- ACTIVITY REGULATION: Inhibited by the antitumor sulfonylurea LY181984,
CC       the vabilloid capsaicin, and retinoids. {ECO:0000269|PubMed:11888291,
CC       ECO:0000269|PubMed:9046026, ECO:0000269|PubMed:9932650}.
CC   -!- INTERACTION:
CC       Q16206-2; Q96Q77: CIB3; NbExp=3; IntAct=EBI-10179508, EBI-10292696;
CC       Q16206-2; Q8TC92: ENOX1; NbExp=3; IntAct=EBI-10179508, EBI-713221;
CC       Q16206-2; P43364-2: MAGEA11; NbExp=3; IntAct=EBI-10179508, EBI-10178634;
CC       Q16206-2; Q6P2C6: MLLT6; NbExp=3; IntAct=EBI-10179508, EBI-5773143;
CC       Q16206-2; P09012: SNRPA; NbExp=3; IntAct=EBI-10179508, EBI-607085;
CC       Q16206-2; O00463: TRAF5; NbExp=3; IntAct=EBI-10179508, EBI-523498;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Secreted, extracellular space.
CC       Note=Extracellular and plasma membrane-associated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16206-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16206-2; Sequence=VSP_015719;
CC   -!- TISSUE SPECIFICITY: Found in the sera of cancer patients with a wide
CC       variety of cancers including breast, prostate, lung and ovarian
CC       cancers, leukemias, and lymphomas. Not found in the serum of healthy
CC       volunteers or patients with disorders other than cancer. Probably shed
CC       into serum by cancer cells. Found on the cell borders of renal, kidney
CC       and ovarian carcinomas but not on the borders of surrounding non-
CC       cancerous stromal cells.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:8150545}.
CC   -!- MISCELLANEOUS: Has several properties associated with prions including
CC       resistance to proteases, resistance to cyanogen bromide digestion, and
CC       the ability to form amyloid filaments resembling those of spongiform
CC       encephalopathies.
CC   -!- SIMILARITY: Belongs to the ENOX family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB30428.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF207881; AAF20934.2; -; mRNA.
DR   EMBL; AK000353; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK289837; BAF82526.1; -; mRNA.
DR   EMBL; AK289812; BAF82501.1; -; mRNA.
DR   EMBL; AL049733; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591908; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471107; EAX11796.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11797.1; -; Genomic_DNA.
DR   EMBL; BC019254; AAH19254.2; -; mRNA.
DR   EMBL; BC140874; AAI40875.1; -; mRNA.
DR   EMBL; AL133207; CAB61581.2; -; mRNA.
DR   EMBL; S72904; AAB30428.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS14626.1; -. [Q16206-1]
DR   CCDS; CCDS14627.1; -. [Q16206-2]
DR   PIR; I54780; I54780.
DR   RefSeq; NP_001268665.1; NM_001281736.1. [Q16206-2]
DR   RefSeq; NP_006366.2; NM_006375.3. [Q16206-2]
DR   RefSeq; NP_872114.1; NM_182314.2. [Q16206-1]
DR   RefSeq; XP_005262411.1; XM_005262354.3.
DR   RefSeq; XP_011529549.1; XM_011531247.2.
DR   RefSeq; XP_011529551.1; XM_011531249.2. [Q16206-1]
DR   RefSeq; XP_011529553.1; XM_011531251.2.
DR   RefSeq; XP_016884715.1; XM_017029226.1.
DR   RefSeq; XP_016884716.1; XM_017029227.1.
DR   RefSeq; XP_016884717.1; XM_017029228.1.
DR   AlphaFoldDB; Q16206; -.
DR   BioGRID; 115758; 32.
DR   IntAct; Q16206; 13.
DR   MINT; Q16206; -.
DR   STRING; 9606.ENSP00000337146; -.
DR   ChEMBL; CHEMBL3714292; -.
DR   DrugBank; DB04915; Idronoxil.
DR   GlyGen; Q16206; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q16206; -.
DR   PhosphoSitePlus; Q16206; -.
DR   BioMuta; ENOX2; -.
DR   DMDM; 34978371; -.
DR   EPD; Q16206; -.
DR   jPOST; Q16206; -.
DR   MassIVE; Q16206; -.
DR   MaxQB; Q16206; -.
DR   PaxDb; Q16206; -.
DR   PeptideAtlas; Q16206; -.
DR   ProteomicsDB; 60838; -. [Q16206-1]
DR   ProteomicsDB; 60839; -. [Q16206-2]
DR   Antibodypedia; 354; 223 antibodies from 30 providers.
DR   DNASU; 10495; -.
DR   Ensembl; ENST00000338144.8; ENSP00000337146.3; ENSG00000165675.19. [Q16206-1]
DR   Ensembl; ENST00000370927.5; ENSP00000359965.1; ENSG00000165675.19. [Q16206-1]
DR   Ensembl; ENST00000370935.5; ENSP00000359973.1; ENSG00000165675.19. [Q16206-2]
DR   Ensembl; ENST00000394363.6; ENSP00000377890.1; ENSG00000165675.19. [Q16206-2]
DR   GeneID; 10495; -.
DR   KEGG; hsa:10495; -.
DR   MANE-Select; ENST00000394363.6; ENSP00000377890.1; NM_006375.4; NP_006366.2. [Q16206-2]
DR   UCSC; uc004evw.5; human. [Q16206-1]
DR   AGR; HGNC:2259; -.
DR   CTD; 10495; -.
DR   DisGeNET; 10495; -.
DR   GeneCards; ENOX2; -.
DR   HGNC; HGNC:2259; ENOX2.
DR   HPA; ENSG00000165675; Low tissue specificity.
DR   MIM; 300282; gene.
DR   neXtProt; NX_Q16206; -.
DR   OpenTargets; ENSG00000165675; -.
DR   PharmGKB; PA162385106; -.
DR   VEuPathDB; HostDB:ENSG00000165675; -.
DR   eggNOG; ENOG502QQ8G; Eukaryota.
DR   GeneTree; ENSGT00390000006788; -.
DR   HOGENOM; CLU_019282_1_1_1; -.
DR   InParanoid; Q16206; -.
DR   OMA; MGIAGQP; -.
DR   OrthoDB; 2962505at2759; -.
DR   PhylomeDB; Q16206; -.
DR   TreeFam; TF323802; -.
DR   PathwayCommons; Q16206; -.
DR   SignaLink; Q16206; -.
DR   SIGNOR; Q16206; -.
DR   BioGRID-ORCS; 10495; 12 hits in 779 CRISPR screens.
DR   ChiTaRS; ENOX2; human.
DR   GeneWiki; ENOX2; -.
DR   GenomeRNAi; 10495; -.
DR   Pharos; Q16206; Tbio.
DR   PRO; PR:Q16206; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q16206; protein.
DR   Bgee; ENSG00000165675; Expressed in calcaneal tendon and 195 other tissues.
DR   ExpressionAtlas; Q16206; baseline and differential.
DR   Genevisible; Q16206; HS.
DR   GO; GO:0005829; C:cytosol; TAS:ProtInc.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016491; F:oxidoreductase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:InterPro.
DR   GO; GO:0022900; P:electron transport chain; IDA:UniProtKB.
DR   GO; GO:0007624; P:ultradian rhythm; IDA:UniProtKB.
DR   CDD; cd12228; RRM_ENOX; 1.
DR   Gene3D; 3.30.70.330; -; 1.
DR   InterPro; IPR038876; ENOX.
DR   InterPro; IPR034140; ENOX_RRM.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   PANTHER; PTHR16001; ECTO-NOX DISULFIDE-THIOL EXCHANGER; 1.
DR   PANTHER; PTHR16001:SF7; ECTO-NOX DISULFIDE-THIOL EXCHANGER 2; 1.
DR   Pfam; PF00076; RRM_1; 1.
DR   SMART; SM00360; RRM; 1.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 1.
DR   PROSITE; PS50102; RRM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Biological rhythms; Cell membrane; Coiled coil;
KW   Copper; Direct protein sequencing; Electron transport; Glycoprotein;
KW   Growth regulation; Membrane; NAD; Oxidoreductase; Reference proteome;
KW   Secreted; Transport.
FT   CHAIN           1..610
FT                   /note="Ecto-NOX disulfide-thiol exchanger 2"
FT                   /id="PRO_0000079275"
FT   DOMAIN          128..207
FT                   /note="RRM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   COILED          293..328
FT                   /evidence="ECO:0000255"
FT   COILED          381..505
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..29
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_015719"
FT   VARIANT         202
FT                   /note="V -> I (in dbSNP:rs754363472)"
FT                   /evidence="ECO:0000269|PubMed:23033978"
FT                   /id="VAR_069427"
FT   MUTAGEN         396
FT                   /note="M->A: No effect on activity but response to
FT                   capsaicin is lost."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         505
FT                   /note="C->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         510
FT                   /note="C->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         546
FT                   /note="H->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         558
FT                   /note="C->A: Period length of activity extended to 42
FT                   minutes."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         562
FT                   /note="H->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         569
FT                   /note="C->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         575
FT                   /note="C->A: Period length of activity extended to 36
FT                   minutes."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         592
FT                   /note="G->V: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   MUTAGEN         602
FT                   /note="C->A: Period length of activity extended to 36
FT                   minutes."
FT                   /evidence="ECO:0000269|PubMed:11888291"
FT   CONFLICT        123
FT                   /note="R -> G (in Ref. 2; AK000353)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311
FT                   /note="E -> G (in Ref. 2; AK000353)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        326
FT                   /note="S -> V (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        328
FT                   /note="I -> V (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="F -> A (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        406..407
FT                   /note="Missing (in Ref. 5; AAH19254)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   610 AA;  70082 MW;  C30BC45730B62A57 CRC64;
     MQRDFRWLWV YEIGYAADNS RTLNVDSTAM TLPMSDPTAW ATAMNNLGMA PLGIAGQPIL
     PDFDPALGMM TGIPPITPMM PGLGIVPPPI PPDMPVVKEI IHCKSCTLFP PNPNLPPPAT
     RERPPGCKTV FVGGLPENGT EQIIVEVFEQ CGEIIAIRKS KKNFCHIRFA EEYMVDKALY
     LSGYRIRLGS STDKKDTGRL HVDFAQARDD LYEWECKQRM LAREERHRRR MEEERLRPPS
     PPPVVHYSDH ECSIVAEKLK DDSKFSEAVQ TLLTWIERGE VNRRSANNFY SMIQSANSHV
     RRLVNEKAAH EKDMEEAKEK FKQALSGILI QFEQIVAVYH SASKQKAWDH FTKAQRKNIS
     VWCKQAEEIR NIHNDELMGI RREEEMEMSD DEIEEMTETK ETEESALVSQ AEALKEENDS
     LRWQLDAYRN EVELLKQEQG KVHREDDPNK EQQLKLLQQA LQGMQQHLLK VQEEYKKKEA
     ELEKLKDDKL QVEKMLENLK EKESCASRLC ASNQDSEYPL EKTMNSSPIK SEREALLVGI
     ISTFLHVHPF GASIEYICSY LHRLDNKICT SDVECLMGRL QHTFKQEMTG VGASLEKRWK
     FCGFEGLKLT
//
